May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
The In Vitro Evaluation of the Ophthalmic Fluoroquinolones Against Bacterial Conjunctivitis Isolates
Author Affiliations & Notes
  • K.A. Yates
    Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, United States
  • R.P. Kowalski
    Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, United States
  • E.G. Romanowski
    Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, United States
  • F.S. Mah
    Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, United States
  • Y.J. Gordon
    Charles T. Campbell Laboratory, University of Pittsburgh, Pittsburgh, PA, United States
  • Footnotes
    Commercial Relationships  K.A. Yates, None; R.P. Kowalski, None; E.G. Romanowski, None; F.S. Mah, None; Y.J. Gordon, None.
  • Footnotes
    Support  NIH Core Grant EY08098 and RPB
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.A. Yates, R.P. Kowalski, E.G. Romanowski, F.S. Mah, Y.J. Gordon; The In Vitro Evaluation of the Ophthalmic Fluoroquinolones Against Bacterial Conjunctivitis Isolates . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2118.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:We determined the in vitro susceptibilities and potencies based on the MICs of recent conjunctivitis isolates against the 3 current ophthalmic fluoroquinolones (FQ) (ciprofloxacin [C], ofloxacin [O], levofloxacin [L]) and the 2 future FQ (gatifloxacin [G], moxifloxacin [M]). Methods: The MICs of 90 bacterial conjunctivitis isolates (8/98 - 9/02) were determined using Etests. The antibiotic susceptibilities were determined using the NCCLS standards. The in vitro susceptibilities and potencies (isolates with the lowest MICs) were compared statistically. Results: QR, QS = Resistant or susceptible to ciprofloxacin and ofloxacin by disc diffusion. Conclusions: The future ophthalmic FQ (G, M) demonstrated increased in vitro potency against Gram-positive pathogens over the current FQ (C, O, L) but no advantage against Gram-negative pathogens. Only 1 FQ (M) demonstrated an increased in vitro susceptibility for 1 pathogen (St. aureus QR) compared to all other FQ. All other susceptibilities were equal. Clinical studies are needed to confirm these in vitro results. Median MIC (µg/ml)  

Keywords: conjunctivitis • antibiotics/antifungals/antiparasitics • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×